Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints chief financial officer

Dr Erik Digman Wiklund succeeds Oystein Soug

Targovax Dr Erik Digman WiklundTargovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.

Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.

He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.

Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.

“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.

“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”

18th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics